Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Carbohydrate Metabolism01:36

Carbohydrate Metabolism

Carbohydrates are polymers composed of molecules containing atoms of carbon, hydrogen and oxygen. One gram of carbohydrate can provide four kilo-calories of energy, which makes it the most efficient instant energy source.
Starch accounts for approximately 60% of the carbohydrates consumed by humans. Since amylase enzymes cannot function in the stomach's acidic environment, starch can only be digested in the mouth and small intestine. Simple sugars are found naturally in milk and fruits in the...
Diabetes Mellitus: Overview and Type I Subtype01:22

Diabetes Mellitus: Overview and Type I Subtype

Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Diabetes Mellitus: Type 2 and Gestational01:22

Diabetes Mellitus: Type 2 and Gestational

Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
Diabetes: Management and Pharmacotherapy01:15

Diabetes: Management and Pharmacotherapy

The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...
Type II Diabetes Mellitus III: Clinical Manifestations and Diagnosis01:25

Type II Diabetes Mellitus III: Clinical Manifestations and Diagnosis

Type 2 diabetes mellitus develops gradually and is often asymptomatic in early stages.Clinical ManifestationsWhen symptoms appear, they include fatigue, blurred vision, pruritus, delayed wound healing, and recurrent infections, particularly candidal infections. Peripheral neuropathy may present as numbness or tingling in the extremities. Classic hyperglycemia symptoms—polyuria, polydipsia, and polyphagia—are less common. Most patients are overweight and frequently have associated hypertension...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Harnessing the potential of data-driven strategies to optimise transfusion practice.

British journal of haematology·2023
Same author

Burden of osteoarthritis in India and its states, 1990-2019: findings from the Global Burden of disease study 2019.

Osteoarthritis and cartilage·2022
Same author

Carrier-Envelope Phase-Dependent Strong-Field Excitation.

Physical review letters·2022
Same author

Long-term cost-effectiveness of Dexcom G6 real-time continuous glucose monitoring system in people with type 1 diabetes in Australia.

Diabetic medicine : a journal of the British Diabetic Association·2022
Same author

Comment on: Bariatric surgery is expensive but improves co-morbidity: 5-year assessment of patients with obesity and type 2 diabetes.

The British journal of surgery·2021
Same author

Development and validation of the risk engine for an Australian Health Economics Model of Osteoporosis.

Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA·2021

Related Experiment Video

Updated: Jul 6, 2026

Improving IV Insulin Administration in a Community Hospital
12:08

Improving IV Insulin Administration in a Community Hospital

Published on: June 11, 2012

Applying some UK Prospective Diabetes Study results to Switzerland: the cost-effectiveness of intensive glycaemic

A J Palmer1, P P Sendi, G A Spinas

  • 1IMIB, Institute for Medical Informatics and Biostatistics, Riehen. DrAJPalmer@excite.com

Schweizerische Medizinische Wochenschrift
|August 23, 2000
PubMed
Summary

Intensive glycemic control with metformin is cost-effective and saves lives for overweight type-2 diabetes patients in Switzerland. This approach improves survival and reduces healthcare costs compared to conventional management.

More Related Videos

A Zebrafish Model of Diabetes Mellitus and Metabolic Memory
10:03

A Zebrafish Model of Diabetes Mellitus and Metabolic Memory

Published on: February 28, 2013

Glycemic Impact on Knee Osteoarthritis Symptoms on Physical, Radiographic, and Inflammatory Markers among Individuals Aged 50 and Over with Diabetes
07:22

Glycemic Impact on Knee Osteoarthritis Symptoms on Physical, Radiographic, and Inflammatory Markers among Individuals Aged 50 and Over with Diabetes

Published on: March 7, 2025

Related Experiment Videos

Last Updated: Jul 6, 2026

Improving IV Insulin Administration in a Community Hospital
12:08

Improving IV Insulin Administration in a Community Hospital

Published on: June 11, 2012

A Zebrafish Model of Diabetes Mellitus and Metabolic Memory
10:03

A Zebrafish Model of Diabetes Mellitus and Metabolic Memory

Published on: February 28, 2013

Glycemic Impact on Knee Osteoarthritis Symptoms on Physical, Radiographic, and Inflammatory Markers among Individuals Aged 50 and Over with Diabetes
07:22

Glycemic Impact on Knee Osteoarthritis Symptoms on Physical, Radiographic, and Inflammatory Markers among Individuals Aged 50 and Over with Diabetes

Published on: March 7, 2025

Area of Science:

  • Pharmacoeconomics
  • Diabetes Management
  • Health Outcomes Research

Background:

  • Overweight type-2 diabetes management presents significant healthcare challenges.
  • The United Kingdom Prospective Diabetes Study (UKPDS) provided key data on metformin's efficacy.
  • Cost-effectiveness of intensive glycemic control needs evaluation in specific healthcare systems.

Purpose of the Study:

  • To conduct a cost-effectiveness analysis of intensive metformin therapy versus conventional control for overweight type-2 diabetes patients in Switzerland.
  • To evaluate the impact on direct costs and survival from a third-party payer perspective.

Main Methods:

  • A Markov model simulated diabetes-related complications using UKPDS probabilities.
  • Costs were sourced from published data, and direct costs over 11 years were calculated.
  • Life expectancy changes were assessed, with extensive sensitivity analysis performed.

Main Results:

  • Intensive metformin control resulted in lower mean costs (CHF 9950 vs. CHF 10,877) over 11 years.
  • Improved survival was observed, with an average gain of 0.43 life-years per patient.
  • Metformin acquisition costs significantly influenced outcomes, alongside event rates for myocardial infarction, renal failure, and stroke.

Conclusions:

  • Intensive glycemic control with metformin is a cost-saving and life-saving strategy for overweight type-2 diabetes patients in Switzerland.
  • The findings support the adoption of intensive metformin management within the Swiss healthcare system.
  • Sensitivity analysis confirmed the robustness of the cost-effectiveness findings.